Histogen Inc

Histogen — Conatus Pharmaceuticals — Piper Jaffray Healthcare Conference 2013

37 slides from Histogen's conference presentation, Dec 3, 2013

  1. Slide 1: Conatus Pharmaceuticals at Piper Jaffray Healthcare Conference

    Slide 1: Conatus Pharmaceuticals at Piper Jaffray Healthcare Conference

    Exhibit 99.1 December NASDAQ:CNAT Piper Pharmaceuticals Conatus Jaffrey 3, 2013 Healthcare Conference

  2. Slide 2: Note Regarding Forward-Looking Statements

    Slide 2: Note Regarding Forward-Looking Statements

    Caution Special This position, current achievements filings some achieved All obligation 2December Pharmaceuticals Conatus forward-looking presentation ofmade and Note on which business orto 3,Forward-Looking anticipated occur with revise 2013 Regarding toare becontains the and strategy, beyond Pipe

  3. Slide 3: San Diego-Based Focused Biotech

    Slide 3: San Diego-Based Focused Biotech

    SanPhase Focused First-in-class, Dual In High Filings Potential Extensive 3December Pharmaceuticals Conatus Diego-Based mechanism unmet planned Pharmaceuticals on 2b toexpertise 3,pursue extending development medical 2013 orally for of Biotech Piper larger US in action active need; and caspase and J

  4. Slide 4: Unmet Need in Chronic Liver Disease

    Slide 4: Unmet Need in Chronic Liver Disease

    Unmet Acute-on-Chronic HCV-Treatment Non-Alcholic ~200,000 ~ PATIENTS 16,000 Overall, 1. 4December Pharmaceuticals Conatus 35 160 Organ MILLION MILLION Americans Need chronic Procurement PATIENTS 3, in 2013 Fatty Liver Failure liver PATIENTS Liver on Piper Liver Disease waiting disease and (HCV-TF)

  5. Slide 5: Emricasan: Pan-Caspase Inhibitor

    Slide 5: Emricasan: Pan-Caspase Inhibitor

    Emricasan 50 Caspase-2 INITIATORS Death Caspase-8 and Caspase Caspase-9 mitochondrial Caspase-3 EXECUTIONERS Apoptosis Caspase-7 Caspase-1 ACTIVATORS Caspase-4 Inflammation 5December Pharmaceuticals Conatus Readout non-enzymatic receptor ICCaspase-6 3/7 Caspase-10 3, 20.0 0.3 2.0 0.2 0.4 0.06 is(nM)

  6. Slide 6: Two Key Clinical Biomarkers: ALT and cCK18

    Slide 6: Two Key Clinical Biomarkers: ALT and cCK18

    Two Key Alanine ALT: Liver cCK18: Apoptosis Independent Pharmaceuticals Conatus Clinically disease Mechanism-specific aminotransferase Biomarkers results studies causes important in release have ALT of Liver demonstrated release (ALT) and ofbiomarker cCK18 Disease validated and intocleaved blood, in

  7. Slide 7: Liver Disease Pathogenesis

    Slide 7: Liver Disease Pathogenesis

    2APOPTOTIC Excessive INSULT Liver INFLAMMATORY 1ACTIVATED Measured December 7Piper Pharmaceuticals Conatus |4 3 | Jaffray 6Fibrosis 5Disease | 7 as Apoptosis |3,8serum 2013 Healthcare |CASPASES CASPASE Pathogenesis Cirrhosis/Decompensation 9 | 10ALT cCK18 CASPASE PlusConference ACTIVATION Excessive

  8. Slide 8: Caspases Plus Excessive Inflammation Are the Key

    Slide 8: Caspases Plus Excessive Inflammation Are the Key

    Caspases 2APOPTOTIC Excessive INSULT Plus Liver INFLAMMATORY 1ACTIVATED Measured December 8Piper Pharmaceuticals Conatus |4 3 |Excessive Jaffray 6Fibrosis 5 | 7are as Apoptosis |3,8serum 2013 Healthcare the |CASPASES CASPASE Cirrhosis/Decompensation 9Inflammation |Key 10ALT cCK18 CASPASE Conference

  9. Slide 9: Emricasan Reduces Apoptosis and Inflammation

    Slide 9: Emricasan Reduces Apoptosis and Inflammation

    Excessive 2APOPTOTIC Rapid EMRICASAN INSULT INFLAMMATORY 1ACTIVATED Measured 9December Pharmaceuticals Conatus |4 3|56and | 7 as Apoptosis sustained |3,8serum 2013 |CASPASES CASPASE 9 | 10 Piper ALT cCK18 CASPASE reductions andJaffray Inflammation ACTIVATION ACTIVATION in Healthcare elevated Reduced

  10. Slide 10: Pre-Clinical Data

    Slide 10: Pre-Clinical Data

    Pre-Clinical Data Pharmaceuticals Conatus

  11. Slide 11: Oral Emricasan Reduces ALT

    Slide 11: Oral Emricasan Reduces ALT

    Oral Emricasan Reduces 100 g/hr) 75 0.75 control) -Fas of 50 ALT 0.0 Control (% 0.03 Dose Hoglen, D-Gln/LPS 2004 December 11 Pharmaceuticals Conatus 50Activity ED50 D- 0.00 0. *p<0.05 0.1 Emricasan 25 100 vol. (mg/kg) * Caspase IP (N.C. 0ALT 0.3 =0.08 control) 309 3, demonstrates ALT 1.0 2013 et Red

  12. Slide 12: Emricasan Reduces Fibrosis in BDL Model

    Slide 12: Emricasan Reduces Fibrosis in BDL Model

    Emricasan BDL Reduces IDN-6556 % area, positive red 20 Sirius 10 Sham Saline Canbay, Experimental December 12 Pharmaceuticals Conatus 50 * 40 Sham p<0.001 BDL 0IDN-6556 *30 A Fibrosis p<0.001 et 3, Reduces Caspase (10 Sham al. 2013 Therapeutics *days) The p<0.003 BDL Piper Inhibition Liver Caspase J

  13. Slide 13: Clinical Experience

    Slide 13: Clinical Experience

    Clinical Experience Pharmaceuticals Conatus

  14. Slide 14: Emricasan Studied in Six Clinical Trials

    Slide 14: Emricasan Studied in Six Clinical Trials

    Emricasan Studied Six Predominately Four Included Emphasis Clinically Reproducible December 14 Pharmaceuticals Conatus Phase randomized, 500+ patients on 1relevant 3, Clinical trials 2013 HCV patients reductions healthy with conducted placebo-controlled Piper results infection Experience liver volun

  15. Slide 15: Phase 2b Studies: Statistically Significant Biomarker Reductions

    Slide 15: Phase 2b Studies: Statistically Significant Biomarker Reductions

    Emricasan Phase Statistically Elevation Use Reduction December 15 Pharmaceuticals Conatus of2b ALT cCK18 Studies at3, in Reduces in significant, baseline: 2013 elevated clinical levels Piper Key inidentifies levels: trials: clinical consistent, Jaffray Biomarkers keytrials: patients Healthcare bioma

  16. Slide 16: Clinical Programs

    Slide 16: Clinical Programs

    Clinical Programs Pharmaceuticals Conatus

  17. Slide 17: Acute-on-Chronic Liver Failure (ACLF)

    Slide 17: Acute-on-Chronic Liver Failure (ACLF)

    Acute-on-Chronic Rapid Follows ~45% Current Liver ~150,000 NEED: December 17 Pharmaceuticals Conatus transplantation likely Deterioration Prevent intervention acute patients 3, to 2013 event die, catastrophic in Liver Piper progress of in involves US may patients Liver Failure and Jaffray beto organ

  18. Slide 18: Emricasan ACLF Phase 2b Trial Design

    Slide 18: Emricasan ACLF Phase 2b Trial Design

    Emricasan ACLF 60-patient, Screening Treatment Phase Emricasan: R mricasan: D M Screen Z T A N IO Admission Hospital N=15 Objectives: Changes Trial December 18 Pharmaceuticals Conatus N=15 Emricasan: EFollow- N=15 Placebo initiated Phase I in25 Follow-Up Phase 3, BID Phase 28-day Day organ biomarker

  19. Slide 19: ACLF Phase 2b Goals

    Slide 19: ACLF Phase 2b Goals

    ACLF Phase Identify Support Provide Relationship Understand Clinical Regional December 19 Pharmaceuticals Conatus exploratory aevent for variation safe 3,End the between 2013 2b: rate dose PK complexities of Goals Piper in Phase and for information co-morbidities reductions Phase PD Jaffray Two/Scie

  20. Slide 20: Severe Renal Impairment Rationale

    Slide 20: Severe Renal Impairment Rationale

    Severe Organ Renal Rationale Kidney ACLF Data NEED: December 20 Pharmaceuticals Conatus inimpairment Failure Phase Renal severe Broaden usually 3, 2013 2b Impairment Progression renal next study ACLF is Piper failure organ a frequent expected and Jaffray to needed CLF fail complication to Healthcare

  21. Slide 21: Emricasan Severe Renal Impairment Phase 1b Study

    Slide 21: Emricasan Severe Renal Impairment Phase 1b Study

    Severe Emricasan Evaluate Goals Potential 2Any 8Logistics Open Single December 21 Pharmaceuticals Conatus Phase patients need label 50 Renal 1PK to mg units for per 3, Phase study broaden in 2013 dose Impairment group in this 1b US Piper adjustment population with Study eligibility Jaffray 8 matchin

  22. Slide 22: Chronic Liver Failure Rationale

    Slide 22: Chronic Liver Failure Rationale

    Chronic Late-stage Rationale Include Different Both Ideal Number Severe Could ~10,000 NEED: December 22 Pharmaceuticals Conatus listed would potentially renal Provide patients Liver of patients etiologies for 3, Liver subjects and be failure 2013 Chronic Failure 1not more with Disease in study use P

  23. Slide 23: ACLF and CLF Are Different Indications

    Slide 23: ACLF and CLF Are Different Indications

    At risk Not Different Example: May ACLF CLF December 23 Pharmaceuticals Conatus as require patients – A –critically keep ofget Separate study transplant developing 3,patients patient different 2013 may endpoints illand be Piper as through is as compensated ACLF the dosing Distinct ahealthy good Jaff

  24. Slide 24: Study Timeline and Dependencies

    Slide 24: Study Timeline and Dependencies

    Study ACLF, 1Q14 ACLF Early Data Repeat Filings Regulatory for Lower Severe at If Proceed December 24 Pharmaceuticals Conatus PK No 50 Pull mg ACLF PK Concerns 2Q14 Dependencies Phase Dose Renal CLF Severe toPhase Concerns 3, CLF 3Q14 and 2013 2b Impairment Renal 2b If Phase Severe No 4Q14 Piper Bet

  25. Slide 25: HCV-Post Orthotopic Liver Transplant

    Slide 25: HCV-Post Orthotopic Liver Transplant

    HCV-Post Rapid Significant Residual ~55% Current Even ~50,000 Delayed STATUS Will December 25 Pharmaceuticals Conatus continually with likely Progression treatments patients Phase HCV Orthotopic newer 3,risk to 2013 immediately 2b/3 progress ofevaluate in HCV accelerated Piper of focus US trial: Fib

  26. Slide 26: Larger Market Opportunity

    Slide 26: Larger Market Opportunity

    Larger Market Opportunity Pharmaceuticals Conatus

  27. Slide 27: Nonalcoholic Steatohepatitis (NASH): An Emerging Opportunity

    Slide 27: Nonalcoholic Steatohepatitis (NASH): An Emerging Opportunity

    Nonalcoholic An Preclinical Compelling NASH Fibrosis Unlike Potential December 27 Pharmaceuticals Conatus Emerging HCV-POLT, study progression for 3, studies preclinical emricasan 2013 in Steatohepatitis Opportunity patients suggest Piper longitudinal ratedata as with Jaffray not fast a in therapeut

  28. Slide 28: Emricasan Reduced Fibrosis in NASH Model

    Slide 28: Emricasan Reduced Fibrosis in NASH Model

    Emricasan In Reduced Chow CDAA 12 Total 10 6F *0% December 28 Pharmaceuticals Conatus ibrosis p<0.05 CSAA: 2experimental * 8CDAA Treated 4fibrosis Choline 3, Preclinical 2013 Placebo Chow models inSupplemented Piper theCSAA Data Choline of Jaffray NASH, inTreated NASH Deficient Healthcare Amino emri

  29. Slide 29: Emricasan Resolution of Hepatic Steatosis in NAFLD Model

    Slide 29: Emricasan Resolution of Hepatic Steatosis in NAFLD Model

    Emricasan In Resolution tissue HFD Reduced HFD—Placebo *1.4 1.2 1.0 (ng/ml) Insulin 0.6 0.3 0.4 *p<0.05 0.0 #0.2 December 29 Pharmaceuticals Conatus The *a0.4 0.1 0.6 0.5 High Treated Placebo homeostasis HOMA 0.8 *p<0.05 Insulin Fat 3, Preclinical of (ng/dL) 2013 Diet Hepatic 0.2 HFD—Treated Levels

  30. Slide 30: NASH Program: Characterize cCK18

    Slide 30: NASH Program: Characterize cCK18

    NASH Characterize cCK18 Use If December 30 Pharmaceuticals Conatus so,data use Program becoming to the 3,explore the 2013 doseeffect an response Piper whether accepted ofJaffray emricasan rationale activity clinical Healthcare on isfor biomarker similar cCK18 HCVConference to for and that inNASH ALT

  31. Slide 31: Tip of a Very Large Iceberg?

    Slide 31: Tip of a Very Large Iceberg?

    Tip of ACLF, ~200,000 HCV-TF, ~35 NAFLD, ~160 While Emricasan December 31 million million ACLF aCLF, Very Viral NASH, patients 3, may patients & 2013 patients and Large Hepatitis, HCV-POLT have ALD CLF Piper Iceberg? much represent Jaffray Other broader Chronic Healthcare large therapeutic unmet Liv

  32. Slide 32: Summary

    Slide 32: Summary

    Summary Pharmaceuticals Conatus

  33. Slide 33: Emricasan Development Programs and Next Milestones

    Slide 33: Emricasan Development Programs and Next Milestones

    Emricasan Indication Acute-on- Severe Impairment Chronic Liver Failure Phase NASH/NAFLD Exploring HCV-POLT Also December 33 Pharmaceuticals Conatus supporting initiate 2b Renal (ACLF) (CLF) Liver Phase trial clinical Phase Preclinical 3, Development initiate options 2013 2H14 Phase to2b initiated in

  34. Slide 34: Financials: Balance Sheet

    Slide 34: Financials: Balance Sheet

    Balance Financials Cash, Note $59,591,948 Accounts Stockholders’ Common Planned $4.7M—ACLF Remainder December 34 Pharmaceuticals Conatus payable cash Sheet use shares payable 3, equivalents toof 2013 $fund equity as IPO 1,000,000 Phase outstanding of& Piper the Proceeds September accrued $ 2b furthe

  35. Slide 35: Executive Management Team

    Slide 35: Executive Management Team

    Executive Steven Charles Chief Alfred Co-founder, Gary SVP December 35 Pharmaceuticals Conatus Clinical C. Executive Financial P. J.J. Burgess, Spada, Mento, Cashion Management 3,SVP President 2013 Research Officer Officer PhD PhD Finance R&D MD Piper && &Team Jaffray Chief & Chief Medical Healthcar

  36. Slide 36: Value Proposition

    Slide 36: Value Proposition

    Value Proposition Emricasan Caspases Clinical Near-term Potential Successful December 36 Pharmaceuticals Conatus programs has to play milestones; 3, is IPO; treat extensive 2013 first-in-class, central well-funded across in Piper areas role experience US entire Jaffray in and of oral underlying to h

  37. Slide 37: Thank You

    Slide 37: Thank You

    THANK YOU! NASDAQ:CNAT Pharmaceuticals Conatus www.conatuspharma.com

Source: SEC EDGAR · 8-K filed Dec 3, 2013

More decks from Histogen Inc